Expression of Concern

No authors listed

No authors listed. Oncologist. 2016 Mar.

. 2016 Mar;21(3):391.

doi: 10.1634/theoncologist.2016-3001.

No abstract available

Expression of concern for

The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy.
Ross JS, Fletcher JA. Ross JS, et al. Oncologist. 1998;3(4):237-252. Oncologist. 1998. PMID: 10388110
The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy.
Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, Symmans WF, Pusztai L, Bloom KJ. Ross JS, et al. Oncologist. 2003;8(4):307-25. doi: 10.1634/theoncologist.8-4-307. Oncologist. 2003. PMID: 12897328 Review.
The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine.
Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. Ross JS, et al. Oncologist. 2009 Apr;14(4):320-68. doi: 10.1634/theoncologist.2008-0230. Epub 2009 Apr 3. Oncologist. 2009. PMID: 19346299 Review.

1. Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy. The Oncologist. 1998;3:237–252. - PubMed
1. Ross JS, Fletcher JA, Linette GP, et al. The Her-2/neu gene and protein in breast cancer 2003: Biomarker and target of therapy. The Oncologist. 2003;8:307–325. - PubMed
1. Ross JS, Slodkowska EA, Symmans WF, et al. The HER-2 receptor and breast cancer: Ten years of targeted anti-HER-2 therapy and personalized medicine. The Oncologist. 2009;14:320–368. - PubMed